Detection of JAK2V617F tyrosine kinase mutation and estimation of serum erythropoietin in blood donors who have high hematocrit
Background: JAK2V617F mutation is the most prevalent molecular abnormality in myeloproliferative neoplasms (MPNs) and has become a valuable marker for diagnosis of MPNs. Almost all patients with polycythemia vera (PV) have this acquired mutation. However, it has also been found in many other hematol...
Main Authors: | Haythem A. AL-Rubaie, May A. Khudeir, Israa M Al-Bayaa |
---|---|
Format: | Article |
Language: | English |
Published: |
College of Medicine University of Baghdad
2015-01-01
|
Series: | مجلة كلية الطب |
Subjects: | |
Online Access: | http://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/554 |
Similar Items
-
JAK2 p.V617F Variants in Non-Blood DNA from Patients with Polycythemia Vera
by: Naoki Mori, et al.
Published: (2023-08-01) -
A mutação JAK2 V617F e as síndromes mieloproliferativas JAK2 V617F mutation and the myeloproliferative disorders
by: Bárbara C. R. Monte-Mór, et al.
Published: (2008-01-01) -
JAK2 Negative Polycythemia Vera
by: Geetha J P., et al.
Published: (2010-07-01) -
JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia
by: Bárbara da Costa Reis Monte-Mór, et al.
Published: (2007-03-01) -
Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera
by: M.E. Bjørn, et al.
Published: (2014-01-01)